Thursday January 01, 1970
Getting past the pilot – lessons in scalability
Taking a great idea that yields positive results at pilot stage and scaling it across an entire organisation is tough, it doesn’t always lead to positive results. A complex and change-resistant industry such as healthcare makes this challenge even harder. So, how do you approach scale in healthcare? This case-study based session features CEOs who have successfully built in their businesses and covers topics including quality, access to care, tech-adoption and organic growth.
Getting past the pilot – lessons in scalability
Taking a great idea that yields positive results at pilot stage and scaling it across an entire organisation is tough, it doesn’t always lead to positive results. A complex and change-resistant industry such as healthcare makes this challenge even harder. So, how do you approach scale in healthcare? This case-study based session features CEOs who have successfully built in their businesses and covers topics including quality, access to care, tech-adoption and organic growth.
Speakers
Explore similar sessions
Getting the most out of your data
How are providers assessing and extracting value from their data? How do you best analyse it to improve outcomes and patient experience? And how do you best analyse it to...



Getting the most out of your data
How are providers assessing and extracting value from their data? How do you best analyse it to improve outcomes and patient experience? And how do you best analyse it to optimise workflow and patient throughput? Three casestudies demonstrate what is possible and the pitfalls to avoid.
Speakers include:
Wolfgang Hofmann, Group head technology and innovation, Fresenius Group
Wolfgang will share how Fresenius is approaching digitalisation, implementing generative AI and moving to the cloud in the complexity of a large organisational structure.
Speakers



The reawakening of nuclear medicine
Nuclear medicine long had its place in the diagnosis and treatment of disease, primarily in cardiology and oncology. Today, the nuclear medicine market is at an inflection point, as the...



The reawakening of nuclear medicine
Nuclear medicine long had its place in the diagnosis and treatment of disease, primarily in cardiology and oncology. Today, the nuclear medicine market is at an inflection point, as the rise of theragnostics and the advent of novel products is expected to nearly quadruple the size of the market in the next 10 years from ~$7bn to $25+bn by 2033. The enormous growth in the field is driven by continued radiopharmaceutical funding where 250+ trials are currently being conducted and by trial funding increasing ~45%+ p.a. between 2019 and 2022. This session features perspectives from a provider, radiopharmaceutical group and OEM on how this is accelerating growth, shaping the market and discussing the medium and long-term obstacles.
Moderation and market overview: Ian Poburenny, Director, Healthcare, Rothschild & Co
Speakers



Building your patient pipeline: How consumerisation is changing the business model
As demand rises and capacity remains a challenge for the public sector globally, patients are turning to self-pay and private medical insurance. With this patients have shifted to become consumers,...






Building your patient pipeline: How consumerisation is changing the business model
As demand rises and capacity remains a challenge for the public sector globally, patients are turning to self-pay and private medical insurance. With this patients have shifted to become consumers, demanding speed, more control over their care pathway and a return on their own investment; increased quality and outcomes. This session features three CEOs who outline how consumerisation has led to new business models, strong brands and long-term patient engagement including how to best building really sticky apps.
Speakers include:
Justin Ash, CEO, Spire
Charlie Bullock, CEO, Scan.com
Speakers





